This Article Full Text (PDF) All Versions of this Article: 1352458507082066v1 1352458507082066v2 14/2/212    most recent References Alert me when this article is cited Alert me if a correction is posted Citation Map Services Email this article to a friend Similar articles in this journal Similar articles in Web of Science Similar articles in PubMed Alert me to new issues of the journal Add to Saved Citations Download to citation manager Request Permissions Request Reprints Add to My Marked Citations Citing Articles Citing Articles via HighWire Citing Articles via Web of Science (4) Citing Articles via Google Scholar Citing Articles via Scopus Google Scholar Articles by Farrell, R. Articles by Giovannoni, G. Search for Related Content PubMed PubMed Citation Articles by Farrell, R. Articles by Giovannoni, G. Social Bookmarking                         What's this?

Neutralizing anti-interferon beta antibodies are associated with reduced side effects and delayed impact on efficacy of Interferon-beta

National Hospital for Neurology and Neurosurgery, Institute of Neurology, Queen Square, London, Royal London Hospital, Queen Mary University of London, r.farrell{at}ion.ucl.ac.uk

R. Kapoor

National Hospital for Neurology and Neurosurgery, Institute of Neurology, Queen Square, London

S. Leary

National Hospital for Neurology and Neurosurgery, Institute of Neurology, Queen Square, London

P. Rudge

National Hospital for Neurology and Neurosurgery, Institute of Neurology, Queen Square, London

AJ Thompson

National Hospital for Neurology and Neurosurgery, Institute of Neurology, Queen Square, London

DH Miller

National Hospital for Neurology and Neurosurgery, Institute of Neurology, Queen Square, London

G. Giovannoni

National Hospital for Neurology and Neurosurgery, Institute of Neurology, Queen Square, London, Royal London Hospital, Queen Mary University of London

Interferon-beta (IFNβ) is a biological therapy which is immunogenic, inducing anti-IFN-β neutralizing antibodies (Nabs) in some subjects. The frequency of Nabs varies depending on IFN-β product and the Nab assay used.

Objective Assess frequency of Nabs using novel Luciferase assay, evaluate association with relapses, frequency of side effects and to compare results with published data.

Methods Serum samples at 12 and 24 months and a follow up sample were tested for binding and Nabs. Titre >20 NU was considered positive. Charts were reviewed retrospectively for clinical data.

Results Out of 327 subjects included, 130 subjects (40%) were binding antibody positive, 89 (27%) were Nab +ve at anytime. Risk at 12 months for being Nab +ve: Avonex 8%, Betaferon 39%, Rebif 33%, P < 10^-5; at 24 months 8, 31 and 27% respectively, P = 0.002. Nab titres were highest in Rebif Nab +ve subjects — 50% >320 NU. Annualized relapse rate was 1.53 pre-treatment, after treatment relapse rate was higher in Nab +ve group 0.67 (95% CI 0.38—0.97) versus 0.5 (0.38—0.61) Nab —ve P = 0.04. Nab status at 12 and 24 months was significantly associated with risk of subsequent relapse, risk being greatest in those with highest titres. Side effects were also significantly associated with Nab —ve status. Multiple Sclerosis 2008; 14: 212—218. http://msj.sagepub.com

Key Words: Multiple Sclerosis • interferon beta • binding antibody • neutralizing antibody • Luciferase assay

This version was published on March 1, 2008

Multiple Sclerosis, Vol. 14, No. 2, 212-218 (2008)
DOI: 10.1177/1352458507082066


CiteULike    Complore    Connotea    Del.icio.us    Digg    Reddit    Technorati    Twitter    What's this?

This article has been cited by other articles:

				D. Hesse, F. Sellebjerg, and P. S. Sorensen Absence of MxA induction by interferon {beta} in patients with MS reflects complete loss of bioactivity Neurology, August 4, 2009; 73(5): 372 - 377. [Abstract] [Full Text] [PDF]